Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Amit Sanyal, MD: A Clinician’s Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Dec
08
Today In Oncology
Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
T-DXd Plus Pertuzumab in HER2-Positive Advanced or Metastatic Breast Cancer
AACR Pediatric Cancer Progress Report 2025
Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo